Form 4: Maze Therapeutics CFO Granted 325,000 Stock Options

Maze Therapeutics' Chief Financial Officer, Tahir Misbah, was granted 325,000 stock options with an exercise price of $15.32.

Summary

• Tahir Misbah, Chief Financial Officer of Maze Therapeutics, Inc., was granted 325,000 stock options.
• The options have an exercise price of $15.32 per share.
• The grant date for these options was September 2, 2025.
• The options begin vesting on September 2, 2026, with 1/4th of the total award vesting.
• Following the initial vesting, 1/48th of the total award will vest monthly thereafter, subject to continued service.
• The options are set to expire on September 1, 2035.

Sentiment

Score: 7

Explanation: The grant of stock options to a key executive is generally a positive signal, indicating commitment and incentivizing long-term performance, though it does not reflect immediate financial results.

Positives

• The grant of stock options to the Chief Financial Officer aligns management's incentives with long-term shareholder value creation.
• The significant number of options (325,000) indicates a substantial equity award, reflecting commitment to the executive.

Risks

• The value of the options is contingent on the company's stock price exceeding the exercise price of $15.32 in the future.
• Vesting of the options is subject to the reporting person's continued service to the Issuer, meaning unvested options could be forfeited upon departure.

Future Outlook

The grant of long-term stock options suggests an expectation of future growth and value creation for Maze Therapeutics, incentivizing the CFO to contribute to the company's long-term success over the vesting and exercise period.

Industry Context

Stock option grants are a standard component of executive compensation packages in the biotechnology and pharmaceutical industries, aiming to attract and retain key talent and align executive interests with long-term shareholder value creation.

Comparison to Industry Standards

• The grant of 325,000 options to a Chief Financial Officer is a significant equity award, which is common for executives in growth-oriented biotech companies like Maze Therapeutics, especially with a multi-year vesting schedule.
• The 10-year expiration period for the options (from grant date to September 1, 2035) is a standard duration for employee stock options in the industry.
• The 4-year vesting schedule (1/4th after one year, then monthly for three years) is a typical industry practice designed to ensure executive retention and long-term commitment.

Related Party Transactions

• Grant of stock options to Chief Financial Officer Tahir Misbah, which is a standard form of executive compensation and an insider transaction.

Stakeholder Impact

• Shareholders: Potential for future dilution if options are exercised, but also potential for increased shareholder value if the CFO's incentives lead to improved company performance.
• Employees: May signal stability in executive leadership and a commitment to long-term growth within the company.

Next Steps

• Monitor future Form 4 filings for any exercise or sale of these options by Tahir Misbah.
• Observe Maze Therapeutics' stock performance relative to the $15.32 exercise price over the vesting and exercise periods.

Key Dates

Keywords

Maze Therapeutics, MAZE, Stock Options, CFO, Tahir Misbah, Executive Compensation, Insider Transaction, Equity Grant